Search

VB10.16

It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting

Procaine

(From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [L1215].

Bupivacaine

Bupivacaine is a widely used local anesthetic agent.

Chlorambucil

(Merck Index, 11th ed)

Osimertinib

[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved

Sodium phosphate, monobasic, unspecified form

Gilteritinib

[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.

Rivastigmine

Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

Tecovirimat

[A35131,A35143] Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox.

Interleukin-7

Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.